Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Gossamer Bio, Inc. (GOSS)

Core Viewpoint - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws, particularly related to the results of its pivotal Phase 3 trial for the drug Seralutinib [1]. Group 1: Company Overview - Gossamer Bio's lead pipeline candidate is Seralutinib, which was evaluated in the PROSERA study for pulmonary arterial hypertension [2]. - The PROSERA trial aimed to demonstrate a treatment effect in a patient population that the company believed was well-suited for the study [2]. Group 2: Trial Results - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that the baseline characteristics were targeted and that the company had "over 90% power given the sample size" [3]. - Despite reaching the planned enrollment target, the primary efficacy endpoint of the trial did not achieve the prespecified level of statistical significance [3].